The growth of the EPS is critical in understanding the current valuation of Accuray. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 2.50% over the last twelve months. The long-term trend in EPS shows how well the management of Accuray is adding value for shareholders.



Accuray is in the healthcare sector and medical devices industry. The company CEO is Joshua H. Levine. Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems.

Previous Intraday Performance:

The ARAY shares had a previous change of 3.64% which opened at 4.90 and closed at 5.12. It moved to an intraday high of 5.13 and a low of 4.85.

SeekingAlpha:  Accuray inks JV in China

Historical Performance:

Over the last five trading days, ARAY shares returned 12.04% and in the past 30 trading days it returned 54.68%. Over three months, it changed 7.56%. In one year it has changed 1.39% and within that year its 52-week high was 5.80 and its 52-week low was 3.17. ARAY stock is 61.77% above its 52 Week Low.

Our calculations result in a 200 day moving average of 4.16 and a 50 day moving average of 3.98. Right now, ARAY stock is trading 23.07% above its 200 day moving average.

PR Newswire:  Accuray And China Isotope And Radiation Corporation Enter Joint Venture Contract To Manufacture And Sell Radiation Oncology Systems In China

Liquidity:

The company has a market cap of $443.7m with 86.7m shares outstanding and a float of 80.4m shares. Trading volume was 1,319,745 shares and has experienced an average volume of 898,898 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Accuray was -0.28 which ended on 30th of June 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.02.

Below was the last reported quarterly earnings per share:
12-31-2018:  -0.05
09-30-2018:  -0.07
06-30-2018:  -0.01
03-31-2018:  -0.10



Base on our calculations, the intrinsic value per share is 3.77, which means it might overvalued by -35.85%

Indicators Also to Watch:

Based on the latest filings, there is 7.30% of insider ownership and 106.40% of institutional ownership.

I calculated the beta to be 2.04

PR Newswire:  Accuray And China Isotope And Radiation Corporation Enter Joint Venture Contract To Manufacture And Sell Radiation Oncology Systems In China

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -5.71%, profit margin is -5.74%, price-to-sales is 1.04 and price-to-book is 9.42.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here